| Bioactivity | HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 µM and 0.84 µM against wild-type and drug resistant HBV strains, respectively[1]. |
| Target | IC50: 0.71 µM (wild-type HBV DNA replication), 0.84 µM (drug resistant HBV DNA replication) |
| Name | HBV-IN-22 |
| CAS | 2338573-94-5 |
| Formula | C26H29N3O2S2 |
| Molar Mass | 479.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qiu J, et al. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem. 2020 Nov 1;205:112581. |
HBV-IN-22
CAS: 2338573-94-5 F: C26H29N3O2S2 W: 479.66
HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 µM and 0.84 µM against wild-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.